Company Overview of ForSight VISION5, Inc.
ForSight VISION5, Inc. evaluates technologies to address patient needs in key ophthalmic markets. The company was incorporated in 2010 and is based in Menlo Park, California.
191 Jefferson Drive
Menlo Park, CA 94025
Founded in 2010
Key Executives for ForSight VISION5, Inc.
Chief Executive Officer, President and Director
Vice President of Finance
Vice President of Marketing
Compensation as of Fiscal Year 2015.
ForSight VISION5, Inc. Key Developments
ForSight VISION5, Inc. Appoints Hector Casab as Vice President of Finance, Effective July 13, 2015
Jul 9 15
ForSight VISION5, Inc. announced the appointment of senior finance executive Hector Casab as Vice President of Finance, effective July 13, 2015. Mr. Casab joins ForSight VISION5 from ophthalmic pharmaceutical company Icon Bioscience, Inc., where as Vice President of Finance and Administration he oversaw all aspects of finance, operations, and administration. Mr. Casab was previously Senior Director, Financial Planning and Analysis, at Onyx Pharmaceuticals, Inc., providing financial management and leadership during Onyx's rapid growth leading up to its acquisition by Amgen. During his five-plus year tenure at Genentech, Mr. Casab's multiple roles included Director, Corporate Planning, Director, Global Supply Chain Finance, and Associate Director, Manufacturing Collaborations Finance. He was previously with Applied Biosystems, serving in various roles in operations and finance.
ForSight VISION5 Announces Completion of Enrollment of Phase 2 Dose-Ranging Study
Jun 11 15
ForSight VISION5 announced the completion of enrollment of 121 subjects in its Phase 2 dose-ranging study, and presentation of Phase 1b data at the World Glaucoma Congress in Hong Kong. The presented data demonstrated that a single administration of its investigational HeliosTM bimatoprost ocular insert provided sustained reduction in intraocular pressure (IOP) for six months. ForSight VISION5 is developing non-invasive ophthalmic products that are designed to replace eye drops and provide sustained therapy for major eye diseases including glaucoma, dry eye, and allergy. The Phase 1b data were collected from a multicenter, prospective, single-arm, open-label, pooled analysis of the bimatoprost ocular insert. The data were presented by Prof. Ivan Goldberg, principal investigator of the Australian study. In this analysis of 27 subjects who met eligibility criteria, mean diurnal IOP at washout was 23.9 mmHg and a mean sustained diurnal IOP reduction of 4.7-6.5 mmHg was observed for 6 months. There were no reported serious or unexpected ocular adverse events. The company continues to advance the clinical development of the Helios insert. The Phase 2 dose-ranging study (FSV5-004) is a prospective, randomized, double-masked, controlled study designed to evaluate the efficacy, safety, and dose-response of two loading doses of the bimatoprost ocular insert compared to a control arm in subjects with open-angle glaucoma or ocular hypertension. The study enrolled 121 subjects at ten clinical sites in the USA in under nine weeks.
ForSight VISION5 Appoints Lisa Garrett as Vice President of Finance and Administration
Oct 16 14
ForSight VISION5 announced that Lisa Garrett has joined the company as Vice President of Finance and Administration from Medtronic. Earlier this year, Medtronic acquired Corventis, Inc., for which Ms. Garrett served as Chief Financial Officer and Vice President, Human Resources. Ms. Garrett brings over 20 years of diversified finance and human resources experience to ForSight VISION5.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|